Post by
Ingiboy on Nov 24, 2023 11:54am
Shiseido
Curious to know what Shiseido is planning to do now that they are not obligated to pay any royalties to Replicel when they move forward with their version of RCH-01 (hijacked from Replicel).
We can only assume their second Trial has been completed as it is now at least 3 years since it started. Were the results compelling enough to take the treatment to market ? Then the questions is outside of Japan where (or can) they market it ?
Next question is Replicel trying to make a deal with Shiseido to sell them the marketing rights to the rest of the world or is Shiseido going to ignore Replicel and market the treatment wherever they want ?
Lastly, what is Replicel working on if they are not negotiating with Shiseido (above) :
Sell the company outright
Move forward with their own version of the hair treatment in Japan
Submit the Dermal Injector for FDA Approval
Sell the Dermal injector
Take Replicel private
I am sure there are many more options.
Comment by
ZeoGak on Nov 24, 2023 2:33pm
FWIW, Shiseido (SSDOY) SP last 5 years:
Comment by
ZeoGak on Nov 24, 2023 2:37pm
OOPS, screen shoot failed. Link: https://www.cnbc.com/quotes/SSDOY?tab=news Scoll and click 5 year on graft
Comment by
Ingiboy on Nov 26, 2023 7:16pm
There is no chance the two biggest shareholders Andrew & Jamie will sell their 27,400,000 shares at $.08 - $.09 when their share average I am sure is in the $.15 - $.20 range.